Levnibiot (Levofloxacin)

Levofloxacin blocks bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. By inhibiting these enzymes, the drug prevents bacterial cells from multiplying, leading to bacterial death and resolution of the infection.

The specific dose of Levnibiot is determined by the prescribing clinician based on the type and severity of infection, patient age, kidney function, and other clinical factors. Patients should follow the prescriber’s instructions and not alter the dose on their own.

Safety of levofloxacin in pregnancy or while nursing has not been definitively established. Clinicians usually weigh potential benefits against possible risks before prescribing to pregnant or lactating women. Patients should discuss any concerns with their healthcare provider.

To request Levnibiot, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Levnibiot (levofloxacin) is a third‑generation fluoroquinolone with broad‑spectrum activity against Gram‑negative and Gram‑positive bacteria. Compared with earlier agents like ciprofloxacin, levofloxacin often offers once‑daily dosing and enhanced activity against respiratory pathogens, though safety considerations remain similar across the class.

Levnibiot tablets should be stored at room temperature, below 25 °C, in the original container to protect them from moisture and light. Keeping the product in a dry place helps maintain its potency throughout its shelf life.

Levnibiot is taken orally, usually with a full glass of water. It can be taken with or without food, but patients should avoid concurrent intake of antacids containing magnesium or aluminum, as these can reduce absorption. The exact schedule is set by the prescriber.

Serious risks include tendon rupture, especially in older adults or those on corticosteroids, QT interval prolongation leading to cardiac arrhythmias, severe allergic reactions such as anaphylaxis, and Clostridioides difficile‑associated colitis. Patients should seek immediate medical attention if they notice sudden tendon pain, palpitations, or severe rash.

Levnibiot is contraindicated in individuals with a known hypersensitivity to levofloxacin or other fluoroquinolones, those with a history of tendon disorders related to fluoroquinolone use, and patients with established QT prolongation without appropriate monitoring. Clinicians should assess each patient’s medical history before prescribing.